Pill form of semaglutide fails to slow Alzheimer’s in large trial
A pill version of semaglutide, the ingredient in Ozempic and Wegovy, did not slow the progress of Alzheimer’s disease, drugmaker Novo Nordisk announced on Nov. 24.
Gut health, GLP-1 and AI – the issues shaping ingredients and NPD – Yahoo
Gut health, GLP-1 and AI – the issues shaping ingredients and NPD Yahoo
GLP-1 Weight-Loss Drug in Pill Form Shows Promise in Trial
By Ernie Mundell HealthDay ReporterTUESDAY, Nov. 25, 2025 (HealthDay News) — New clinical trial results bode well for what could be the first GLP-1…
PrecisionLife and Ovation Partner to Develop Precision Medicine Test to Inform Reimbursement of GLP-1 Anti-Obesity Drugs
Collaboration to support value-based reimbursement models for GLP-1 receptor agonists, optimizing patient outcomes, increasing markets, and healthcare sustainability. OXFORD, England and PORTLAND, ME, Nov. 25, 2025 /PRNewswire/ — Ovation.io, a leading human omics and clinical data…
Two Alzheimer’s Trial Failures Reveal Clinical Challenges
Two major clinical disappointments Johnson & Johnson’s anti-tau antibody and Novo Nordisk’s GLP-1 metabolic therapy underscore just how complex and Alzheimer’s remains.
Gut health, GLP-1 and AI – the issues shaping ingredients and NPD
At the Next Generation Ingredients 2025 conference, speakers from across the industry explored how health innovation and ethical sourcing are shaping consumer expectations. The post Gut health, GLP-1 and AI – the issues shaping ingredients and NPD appeared first on Just Food.
Akston Initiates Clinical Trial of Once-Weekly GLP-1 Weight-Management Therapy for Cats
Cornell University-led study evaluates novel protein therapy designed to help cats achieve a healthier body condition with convenient once-a-week dosing BEVERLY, Mass., Nov. 25, 2025 /PRNewswire/ — Akston, the Biotech Built for Pets, announced today the start of a clinical study at…
Assessment of thyroid cancer risk associated with glucagon‐like peptide 1 receptor agonist use
Abstract Aims Published literature has raised concerns regarding a causal association between glucagon-like peptide 1 receptor agonist (GLP-1RA) use and thyroid cancer risk in adults. In this analysis, we evaluated the association between thyroid cancer risk and GLP-1RA use. Materials and Methods Our evaluation included data from (i) 93 liraglutide or semaglutide phase 2 and […]
Michelle Obama sparks Ozempic weight loss rumors with new photoshoot
Former US first lady, Michelle Obama has sparked Ozempic weight loss rumors after she showed off a seemingly slimmer figure in a new photoshoot. Obama, 61, posed in the new shoot by famed photographer Annie Leibovitz, sharing behind-the-scenes footage on her social media.Before now, the author and podcast host’s fashion choices have been lauded by many, with […]
Novo Nordisk Shares Dropped 12% as Semaglutide Fails Alzheimer’s Trial
Novo Nordisk shares dropped 12% after the company announced that semaglutide, the GLP-1 drug behind Ozempic and Wegovy, failed to show any benefit in slowing cognitive decline in early Alzheimer’s disease. The phase 3 EVOKE and EVOKE-Plus trials found no meaningful difference between semaglutide and placebo on key cognitive and functional measures, prompting Novo Nordisk […]